Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery

Clinical Validation and Distribution Expansion Drive Incremental Growth for ScleroSafe Platform

By The Northwire Desk — AI Analysis Apr 30, 2026 · 08:30 TSXV:
Executive Summary
  • VVT Med Inc. announced the publication of peer-reviewed clinical data in the Indian Journal of Vascular and Endovascular Surgery on April 30, 2026.
  • The study evaluated the ScleroSafe catheter-directed sclerotherapy system for symptomatic primary varicose veins.
  • Results showed a 100% clinical success rate in 30 patients with 95% vein occlusion at day 30 and 92% at day 90.
  • No serious complications such as deep vein thrombosis or skin necrosis were observed during the 90-day follow-up.
  • On April 27, 2026, VVT Med signed its largest European distribution agreement with Uber Ros S.p.A. for Italy, Vatican City, and San Marino.
  • The five-year agreement includes minimum purchase commitments valued at approximately CAD $2.3 million in potential revenue.
  • Uber Ros S.p.A. also participated as an investor in the Company's non-brokered private placement.
  • CapitaLynx Ltd was engaged for Investor Relations services at a cost of US$12,500 per month after an initial term.
Material Impact
  • The clinical data provides external validation but is based on a small observational cohort (30 patients), which limits statistical significance compared to randomized controlled trials typically required for major valuation inflection points.
  • While the 100% success rate is positive, it aligns with existing FDA-cleared and CE-marked status claims rather than introducing new regulatory milestones that would fundamentally alter risk profiles.
  • The distribution agreement adds revenue visibility but represents a modest annualized run-rate (~$460k/year) relative to typical small-cap medtech expectations unless the company is pre-revenue or early-stage.
  • Investor participation by Uber Ros signals confidence in the product's fit within their portfolio, yet the total size of the private placement remains undisclosed, leaving dilution risk ambiguous.
  • The engagement of an IR firm at a fixed monthly cost introduces a recurring cash burn expense that must be weighed against liquidity needs.
  • Overall, the news reinforces the commercialization thesis without materially de-risking the investment to the extent of warranting a "Game Changer" classification in a risk-averse framework.
TSXV: · Price
Company Overview
  • VVT Med Inc. develops the ScleroSafe system, a non-thermal, non-tumescent (NT-NT) technology for treating venous disease.
  • The platform utilizes simultaneous sclerosant injection and blood aspiration to treat varicose veins.
  • The product holds FDA clearance and CE marking status prior to these news releases.
  • Flagship project is the commercialization of ScleroSafe in global markets, with recent focus on European expansion (Italy) and clinical validation in India.
Read the original news release →

More from

Jun 11, 2026 · 08:30

VVT Med Advances Global Commercial Rollout of ScleroSafe with Dominican Republic Entry and Tranche 2 Financing

Financings May 26, 2026 · 08:00

VVT Med Executes European Rollout with First Italian Patient Treatments Following Strong Clinical Validation

Production / Operations Apr 27, 2026 · 09:00

VVT Med Secures Italian Distribution with Investor Participation, Incremental Revenue Stream Established

M&A / Property